Halimu N. Haliduola

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

Piotr Wiland, Sławomir Jeka, Eva Dokoupilová et al. · BioDrugs · 2020 · 37 citations · Full text

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods

Oliver von Richter, Lena Lemke, Halimu N. Haliduola et al. · Expert Opinion on Biological Therapy · 2019 · 36 citations · Full text

Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

Steven R. Feldman, Nataliya Reznichenko, Grażyna Pulka et al. · BioDrugs · 2021 · 30 citations · Full text

Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis

Steven R. Feldman, Nataliya Reznichenko, Fausto Berti et al. · Expert Opinion on Biological Therapy · 2023 · 22 citations · Full text

Missing data imputation using utility-based regression and sampling approaches

Halimu N. Haliduola, Frank Bretz, Ulrich Mansmann · Computer Methods and Programs in Biomedicine · 2022 · 14 citations · Full text

Imbalanced Learning Problems, Engineering, Machine Learning +14